Sign in
CompletedPhase 3

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Key facts

Who runs it
GlaxoSmithKline
Where
Belgium, Canada, Finland, Panama, South Korea, Spain, and Taiwan10 sites in 7 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
68 people enrolled
Started
9 Dec 2019
Ended
27 Jun 2024
Type of study
Interventional
Treatments tested
  • HZ/su vaccine (GSK1437173A)
Record updated
18 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Inclusion criteria for enrolment; Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and subjects' Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol; Written informed consent obtained from the subject/LAR(s) of the subject prior to performance of any study-specific procedure; Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course
  • Inclusion criteria for revaccination; Subjects receiving maintenance CIS therapy for the prevention of allograft rejection for a minimum of one month prior to the first revaccination; Subjects without an episode of allograft rejection within 90 days prior to the first revaccination visit; Female subjects of non-childbearing potential may be revaccinated. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause; Female subjects of childbearing potential may be revaccinated, if the subject:
  • has practiced adequate contraception for 30 days prior to revaccination, and
  • has a negative pregnancy test on the day of revaccination, and
  • has agreed to continue adequate contraception up to 2 months after completion of the revaccination series

Who cannot take part

  • Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study; Prior/Concurrent clinical study experience
  • Concurrently participating in another interventional vaccine or immunosuppressive clinical study, in which the subject is exposed to an investigational or a non-investigational vaccine/product (drug) at any time during the ZOSTER-073 study
  • Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study or make vaccination unsafe; Prior/Concomitant therapy
  • Administration or planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first revaccination dose of study vaccine and ending at Visit 5 (Month 26)
  • Use of anti-CD20 or other B-cell monoclonal antibody agents as maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months of first revaccination dose of study vaccine
  • Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of maintenance immunosuppressive therapies
  • Planned administration/administration of a live vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration
  • Planned administration/administration of a non-replicating or subunit vaccine, not foreseen by the study protocol, in the period starting 8 days before and ending 30 days after each dose of study vaccine; Other exclusion criteria for revaccination
  • Significant underlying illness that, in the opinion of the investigator, is expected to prevent completion of the study
  • History of confirmed HZ within one year before revaccination visit (Visit 3)
  • Any additional confirmed or suspected immunosuppressive or immunodeficient condition
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe
  • Vaccination against HZ since completion of study ZOSTER-041
  • More than one organ transplanted
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions up to 2 months post-revaccination Dose 2

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study also assessed immune responses as well as safety after revaccination with 2 additional doses of the HZ/su administered at 6 to 8 years after the 2-dose primary vaccination course.

The group in the trial

  • HZ/su GroupTreatment being tested

    Participants with renal transplant who completed the 2-dose Herpes Zoster (HZ/su) vaccination course in the primary ZOSTER-041 (NCT02058589) study were enrolled in the current ZOSTER-073 (NCT04176939) study. 47 of these participants further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of the current ZOSTER-073 (NCT04176939) study, first dose at Month 24 and second dose at Month 25.

    Treatment: HZ/su vaccine (GSK1437173A)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
Publications
Record updated
18 July 2025